Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
This article aims to provide a clinically practical approach to PCNSL, including special considerations for older patients and those with impaired renal function. The benefits and risks of HD-MTX or high-dose chemotherapy with autologous stem cell transplantation versus other, better tolerated strategies are also discussed. In all settings, the preferred treatment is always enrollment in a clinical trial if one is available.
PMID: 33152700 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lymphoma | Methotrexate | Neurology | Primary CNS Lymphoma | Radiation Therapy | Revlimid | Rituxan | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants